Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2025Frontiers in OncologyOpen Access

TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMarwah AlbakriTaibah University

Discussion

Loading...

Member takes

Implication

This review highlights immune dysregulation and tumor microenvironment in TP53-mutated MDS and AML, suggesting novel therapeutic strategies.

Key Points

  • TP53 mutations lead to immune dysregulation and poor survival in myelodysplastic syndromes.
  • Current therapies show limited efficacy, such as chemotherapy, with overall poor survival for high-risk patients.
  • Emerging therapeutic strategies include immune modulation and metabolic interventions to address these challenges.
  • The integration of targeted therapies may improve patient outcomes in TP53-mutated MDS and AML.

Cite This Study

Marwah Albakri (2025) studied this question.

synapsesocial.com/papers/68af4eaead7bf08b1ead72a9https://doi.org/10.3389/fonc.2025.1655486
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies2019 · 161 citations
  2. 2Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment2019 · 307 citations
  3. 3Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia2017 · 19 citations
  4. 4Targeting Wnt signaling in acute myeloid leukemia stem cells2021 · 11 citations
  5. 5GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML2017 · 91 citations